var title_f9_23_9584="Doppler pulmonary regurgitation";
var content_f9_23_9584=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In most normal individuals pulmonary regurgitant can be detected with color flow Doppler and a well defined signal of pulmonary regurgitation can be recorded using pulsed or continuous wave Doppler. In this pulsed wave study, the forward flow in the pulmonary artery during systole is laminar. The regurgitant diastolic flow has a relatively slow slope of decay (arrows). In severe pulmonary regurgitation, the diastolic decay can be very rapid and the systolic signal dense. Respiratory variation in the slope of the diastolic signal can be seen. The velocity of end diastolic flow signal can be used to calculate end diastolic pulmonary pressure by applying the Bernoulli equation and adding the right atrial pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9584=[""].join("\n");
var outline_f9_23_9584=null;
var title_f9_23_9585="Rufloxacin: International drug information";
var content_f9_23_9585=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rufloxacin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Monos (IT);",
"     </li>",
"     <li>",
"      Qari (IT);",
"     </li>",
"     <li>",
"      Tebraxin (IT);",
"     </li>",
"     <li>",
"      Uroflox (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F3335217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Rufloxacin Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3335218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F3335219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible infections of the lower urinary tract (cystitis, pyelonephritis, and chronic prostatitis)",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F3335241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Usual dose: 400 mg, followed by 200 mg/day; 400 mg/day should be reserved for more severe infections (chronic pyelonephritis); duration: 5-10 days for acute infections, longer for more serious infections (up to 4 weeks for bacterial prostatitis)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3335242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 200 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10503 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9585=[""].join("\n");
var outline_f9_23_9585=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302647\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335217\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335218\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335219\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335241\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821147\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335242\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10503\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10503|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_23_9586="Myofascial pelvic pain map";
var content_f9_23_9586=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Female myofascial pelvic pain documentation map",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 664px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9586=[""].join("\n");
var outline_f9_23_9586=null;
var title_f9_23_9587="Hemangioblastoma NSE";
var content_f9_23_9587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Hemangioblastoma immunohistochemistry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 168px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrographs of immunoperoxidase staining for neuron specific enolase (NSE) on the left and the intermediate filament vimentin on the right. The neoplastic stromal cells react in a perinuclear and perivacuole pattern (brown staining) with NSE. These cells are filled with vimentin, which demarcates the many cytoplasmic vacuoles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric T Wong, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9587=[""].join("\n");
var outline_f9_23_9587=null;
var title_f9_23_9588="Lidocaine and epinephrine: Patient drug information";
var content_f9_23_9588=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lidocaine and epinephrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/52/29510?source=see_link\">",
"     see \"Lidocaine and epinephrine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/12/38084?source=see_link\">",
"     see \"Lidocaine and epinephrine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lignospan&reg; Forte;",
"     </li>",
"     <li>",
"      Lignospan&reg; Standard;",
"     </li>",
"     <li>",
"      Xylocaine&reg; MPF With Epinephrine;",
"     </li>",
"     <li>",
"      Xylocaine&reg; With Epinephrine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xylocaine&reg; With Epinephrine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb an area of the skin before care.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lidocaine, epinephrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma, myasthenia gravis, shock, or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11556 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9588=[""].join("\n");
var outline_f9_23_9588=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188651\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188652\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025665\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025664\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025669\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025670\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025672\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025667\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025668\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025673\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025674\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/52/29510?source=related_link\">",
"      Lidocaine and epinephrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/12/38084?source=related_link\">",
"      Lidocaine and epinephrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_23_9589="Trandolapril: Patient drug information";
var content_f9_23_9589=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Trandolapril: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=see_link\">",
"     see \"Trandolapril: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mavik&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mavik&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691388",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help heart function after a heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703059",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to trandolapril or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11111 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-201.248.109.99-10E284DFB3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9589=[""].join("\n");
var outline_f9_23_9589=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229781\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229782\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020773\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020775\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020774\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020779\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020780\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020782\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020777\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020778\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020783\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020784\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=related_link\">",
"      Trandolapril: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_23_9590="Inverted papilloma";
var content_f9_23_9590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Inverted papilloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 204px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A-B, At low power (A, 10x), anastomosing cords of normal appearing urothelium originating from the overlying mucosa are growing downward into the stroma. At higher power (B, 20x), the periphery of the cords displays palisading basal cells, while the central portion contains urothelial cells. The stromal component is mostly minimal and lacks inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9590=[""].join("\n");
var outline_f9_23_9590=null;
var title_f9_23_9591="Pathophysiology of the long QT syndrome";
var content_f9_23_9591=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of the long QT syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/23/9591/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/23/9591/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/23/9591/contributors\">",
"     Mark E Josephson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/23/9591/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/23/9591/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/23/9591/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/23/9591/contributors\">",
"     Samuel Asirvatham, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/23/9591/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/23/9591/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/23/9591/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long QT syndrome (LQTS) is the phenotypic description of a group of disorders that are defined by two characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolongation of the QT interval",
"     </li>",
"     <li>",
"      A characteristic arrhythmia, polymorphic ventricular tachycardia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The LQTS can be congenital, as an inherited disorder usually involving a mutation of an ion channel gene, or can be acquired as an adverse response to medication, metabolic abnormalities, or bradyarrhythmias (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Torsades de pointes (TdP) or \"twisting of points\" is the specific type of polymorphic ventricular tachycardia (VT) associated with either form of the LQTS.",
"   </p>",
"   <p>",
"    There are some pathophysiologic differences between the acquired and congenital forms of the LQTS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the acquired form, polymorphic VT is most commonly precipitated by a characteristic sequence of long-short RR intervals. This interval is normally caused by a ventricular premature beat followed by a compensatory pause (",
"      <a class=\"graphic graphic_waveform graphicRef73827 \" href=\"UTD.htm?42/7/43134\">",
"       waveform 1",
"      </a>",
"      ). Polymorphic VT can similarly occur in association with bradycardia or frequent pauses; as a result, the acquired form of LQTS is called \"pause-dependent\" LQTS [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the inherited or congenital form, particularly with certain genotypes, TdP typically follows a sudden adrenergic surge. Such patients are considered to have \"catecholamine-dependent\" LQTS [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these distinctions are not absolute. As an example, one observational study of 15 patients with congenital LQTS documented \"pause-dependent\" TdP, which is more characteristic of the acquired form, in 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology of the long QT syndromes will be reviewed here. The causes, genetics, diagnosis, prognosis, and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link\">",
"     \"Diagnosis of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link\">",
"     \"Prognosis and management of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the relatively simple clinical definition of LQTS applies to both acquired and the variety of congenital forms, the pathophysiology of the disorder is complex, incompletely understood, and probably varies among patients. Two leading pathophysiologic hypotheses have emerged to explain commonly observed features of LQTS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extensive and growing clinical and genetic evidence supports the importance of derangements in cardiac ion flows, resulting in prolongation of the action potential (",
"      <a class=\"graphic graphic_figure graphicRef63732 \" href=\"UTD.htm?0/57/927\">",
"       figure 1",
"      </a>",
"      ). Based upon these data, congenital LQTS is considered a disease of ion channels. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"       \"Genetics of congenital and acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The observation that the immediate trigger for TdP in the inherited form is often a sudden surge in sympathetic tone (a feature not seen in the acquired form) led to the hypothesis that the congenital LQTS may be caused by an imbalance in the sympathetic innervation of the heart.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Derangements in ion flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the leading pathophysiologic hypotheses focuses on derangements in cardiac ion flow, leading to increases in the action potential duration, early afterdepolarizations and triggered activity. The latter change can be due both to an increase in time for repolarization and to oscillations in membrane potential called early afterdepolarizations (EADs) which are a form of triggered activity. Abnormalities in ion flow that prolong the action potential duration may lead to arrhythmias via reentrant mechanisms as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     The normal action potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of normal cardiac cell electrophysiology is required in order to fully appreciate the proposed alteration in ion currents and electrophysiologic mechanisms which may underlie the long QT syndromes. The normal action potential (AP) is composed of the following five phases, beginning with phase four (",
"    <a class=\"graphic graphic_figure graphicRef71390 \" href=\"UTD.htm?15/55/16253\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61058 \" href=\"UTD.htm?31/46/32481\">",
"     movie 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phase 4 represents the normal",
"      <strong>",
"       diastolic",
"      </strong>",
"      resting membrane potential of myocardial cells. Myocardial ventricular cell membranes during diastole are polarized at -90 mv (ie, the resting membrane potential), which largely represents the equilibrium potential for potassium. This occurs because most resting cardiac cell membranes are much more permeable to potassium than to sodium ions.",
"     </li>",
"     <li>",
"      Phase 0 occurs when the membrane potential reaches -60 mv. A rapid inward flow of sodium ions through the fast sodium channels ensues and",
"      <strong>",
"       depolarizes",
"      </strong>",
"      the cell membrane. Inward current during phase 0 is also sustained by activation of L and T type calcium channels.",
"     </li>",
"     <li>",
"      Phase 1 represents an initial repolarization after the overshoot of phase 0 and is caused by a transient outward potassium current.",
"     </li>",
"     <li>",
"      Phase 2 is called the plateau phase, because it represents an equilibrium between the inward calcium and delayed sodium currents and the outward potassium current (known as the delayed rectifier potassium current).",
"     </li>",
"     <li>",
"      Phase 3 represents the rapid repolarization which occurs when outward potassium current dominates over the decaying inward calcium current. Repolarization is predominantly effected through the outward (delayed) rectifying potassium current. These channels open in response to depolarization and allow potassium to flow out of cells and repolarize the membrane potential toward its resting level. The QT interval on the surface electrocardiogram is determined by the activity of these channels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Prolonged repolarization and EADs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolongation of the QT interval may be associated with the presence of early afterdepolarizations (EADs). EADs are single or multiple oscillations of the membrane potential that can occur during phase 2 or 3 of the action potential. EADs occur in association with prolongation of the repolarization phase of the action potential.",
"   </p>",
"   <p>",
"    Prolongation of repolarization results from a",
"    <strong>",
"     net reduction in the outward current",
"    </strong>",
"    , due to an increase in inward current, a decrease in outward current, or both. This may occur by one or more of three ionic mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation of a delayed sodium current which occurs early during repolarization. This is the mechanism responsible for the QT prolongation seen with the drug",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"       ibutilide",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increased inward calcium current. Increases in intracellular calcium are caused by an elevation in transsarcolemmal calcium current due to either catecholamines or a rise in the extracellular calcium concentration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If occurring in phase 2 of the action potential, EADs are thought to be caused by increased inward current through L-type calcium channels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/6\">",
"     6",
"    </a>",
"    ] or through the sodium-calcium exchanger [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/7\">",
"     7",
"    </a>",
"    ]. Depolarizing currents occurring late in phase 3 are thought to be due to inward currents through T-type calcium channels or sodium channels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decreased outward potassium current. This decreased outward current can be caused by either class IA or III antiarrhythmic drugs. Class IA agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      ) block the outward delayed rectifier potassium current; in contrast, class III antiarrhythmic drugs (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      ) block the rapid component of the delayed outward rectifier with a minimal effect on the inward rectifier current.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Triggered activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triggered responses or triggered activity are EADs that reach threshold potential, depolarize cell membranes, and result in additional action potentials. Propagation of these triggered responses produce ventricular premature depolarizations that may initiate polymorphic VT (TdP) in susceptible subjects. EADs and triggered responses are particularly easy to induce in Purkinje fibers and M cells, a group of cells in the left ventricular free wall which have recently been identified as the site of EAD-induced triggered activity after exposure to drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Common precipitants of EADs and triggered activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of EADs is potentiated by bradycardia, hypokalemia, hypomagnesemia and a long list of medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .) A few notable examples deserve emphasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bradycardia &mdash; Slow heart rates are associated with increased inactivation of the outward repolarizing potassium current and a reduction in the Na-K-ATPase pump outward current (3 Na",
"      <span class=\"nowrap\">",
"       out/2",
"      </span>",
"      K in = net outward positive current). Slow heart rates also enhance the activity of certain antiarrhythmic drugs on repolarization (ie, repolarization and the QT interval are more prolonged). This property is called reverse use dependence and can lead to ion fluxes that facilitate EADs and TdP.",
"     </li>",
"     <li>",
"      Hypokalemia &mdash; Low potassium levels lead to decreased outward repolarizing current via reductions in electrogenic Na-K-ATPase pump activity and outward potassium channel activity.",
"     </li>",
"     <li>",
"      Antiarrhythmic drugs &mdash; Class IA antiarrhythmic agents block both sodium and potassium channels, while the class III drugs block the potassium channels (",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"       table 1",
"      </a>",
"      ). Blockade of sodium channels would be expected to shorten the action potential duration, whereas blockade of potassium channels should prolong the action potential duration. At slow heart rates and low to normal concentrations of Class IA drugs, the potassium channel blocking activity predominates over the effect on the sodium channel [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/11\">",
"       11",
"      </a>",
"      ]. Therefore, EADs and TdP are more frequently seen with nontoxic levels of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ; supratherapeutic levels lead to increased sodium channel blocking activity and are rarely associated with QT prolongation and TdP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    d,l-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    (a class III antiarrhythmic drug with beta blocking activity) and the pure class III agents, such as d-sotalol (and probably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ), are potassium channel blockers that cause QT prolongation and are associated with TdP. Proarrhythmia, primarily TdP, occur in 2 to 7 percent of patients taking d,l-sotalol at doses of at least 320",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    this complication is dose-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    d-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    , the isomer of d,l-sotalol, is a pure class III agent that does not affect beta adrenergic receptors. It is associated with an increased rate of arrhythmias, including TdP as shown in the SWORD (Survival With Oral D-sotalol) trial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/13\">",
"     13",
"    </a>",
"    ]. These findings led to the withdrawal of d-sotalol from the market.",
"   </p>",
"   <p>",
"    Like other class III antiarrhythmic agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    prolongs the time for repolarization in atrial and ventricular myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/14\">",
"     14",
"    </a>",
"    ]. This effect is mediated by activation of a slow, delayed inward sodium current that occurs early during repolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/5\">",
"     5",
"    </a>",
"    ]. This is different from other class III agents which act by inhibiting outward potassium currents. In one report, nonsustained TdP occurred in 2.7 percent of patients treated with ibutilide, while a sustained event was seen in 1.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    , a complex antiarrhythmic agent with potassium channel blocking activity, causes QT prolongation but is rarely associated with TdP. This disparate result may be due to the drug's multiple actions, including the blockade of sodium, potassium, and calcium channels, and of alpha and beta adrenergic receptors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of drug-induced blockade of the rapidly activating delayed rectifier current appears to be dependent upon the extracellular potassium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/16\">",
"     16",
"    </a>",
"    ]. Low extracellular potassium increases the drug block, while there is relative resistance to block when extracellular potassium levels are elevated as may occur with myocardial ischemia or rapid heart rates. This relationship may explain the reverse use-dependent effect of these drugs, ie, the degree of prolongation of repolarization is reduced as the stimulation rate increases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      &mdash; Ketoconazole and erythromycin both inhibit CYP3A. Individuals with low CYP3A activity may therefore be unable to oxidize drugs such as terfenadine, astemizole (both of which have been taken off the market), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      when they are concurrently taking ketoconazole or erythromycin. These effects may lead to QT prolongation, resulting in TdP [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/17\">",
"       17",
"      </a>",
"      ]. In addition, erythromycin alone can cause QT prolongation and TdP [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/10,18\">",
"       10,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV infection &mdash; QT prolongation and TdP have been reported in patients with HIV infection, even in the absence of drug therapy. In one study, 29 percent of hospitalized patients with HIV infection had QT prolongation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/19\">",
"       19",
"      </a>",
"      ]. Postulated mechanisms include myocarditis, a subclinical cardiomyopathy, or autonomic neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Increased sympathetic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence supporting the significance of sympathetic activity in LQTS includes observations on the impact of the stellate ganglia. The activity of the left sympathetic stellate ganglion is greater than that of the right ganglion in normal individuals. In addition, the left stellate ganglion innervates the majority of the ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/12,21\">",
"     12,21",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Increased activity of the left stellate ganglion or reduced activity of the right stellate ganglion leads to increased sympathetic innervation of the heart. Studies in both animals and humans have demonstrated that right stellectomy or stimulation of the left stellate ganglion both prolong the QT interval and alter T wave morphology in a manner that mimics the surface ECG found in patients with LQTS. Furthermore, in a computer model sympathetic stimulation facilitated the induction of TdP by a number of mechanisms, including [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreasing the refractory period",
"     </li>",
"     <li>",
"      Permitting earlier premature stimulation",
"     </li>",
"     <li>",
"      Allowing reentry in the presence of the shorter refractory period",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, sympathetic stimulation can also facilitate the induction of triggered activity and early after potentials (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Prolonged repolarization and EADs'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Indirect clinical evidence also supports the hypothesis that increased sympathetic activity may underlie the pathophysiology of congenital LQTS. One study found that an infusion of epinephrine increased both transmural and spatial dispersion of repolarization in patients with LQTS; this effect was more pronounced in LQT1 compared to LQT2, possibly explaining why LQT1 patients are more sensitive to sympathetic stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, antiadrenergic therapies, including beta blockers and left sympathectomy, substantially reduce the risk of TdP in patients with LQTS, despite the fact that they do not shorten the QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link&amp;anchor=H8#H8\">",
"     \"Prognosis and management of congenital long QT syndrome\", section on 'Importance of genotype'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link&amp;anchor=H9#H9\">",
"     \"Prognosis and management of congenital long QT syndrome\", section on 'Clinical course'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional support for the role of enhanced sympathetic activity comes from a study in which the heart rate was increased by atrial pacing in the absence of sympathetic stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/24\">",
"     24",
"    </a>",
"    ]. In this setting, the QT interval shortened and QT dispersion (as determined by monophasic action potential duration) decreased in both control and LQTS patients. An infusion of epinephrine during atrial pacing blunted these effects on repolarization in the patients with LQTS but not the controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dispersion of repolarization and reentry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the dispersion of repolarization and reentry may be other potential mechanisms for the development of TdP. Dispersion of repolarization refers to an inhomogeneity in repolarization or recovery of excitability in a region of myocardium. A specific population of cells in the myocardium, called M cells, demonstrate marked prolongation of action potential duration in response to drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Dispersion of repolarization could therefore occur in response to these drugs if the action potential is prolonged in M cells but not in the surrounding myocardium. The result is a functional block in the M cell region, providing the necessary milieu for the development of a reentrant arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=see_link\">",
"     \"QT dispersion: Measurement and interpretation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=see_link\">",
"     \"QT dispersion: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initiation and maintenanance of VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;EADs and triggered activity are thought to be the most common initiating mechanism for the ventricular ectopy and polymorphic VT associated with long QT intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/17,25\">",
"     17,25",
"    </a>",
"    ]. Alterations in sympathetic activity and dispersion of repolarization probably contribute to the electrophysiologic milieu that facilitates malignant arrhythmias, at least in certain cases.",
"   </p>",
"   <p>",
"    Maintenance of a sustained ventricular arrhythmia may be due to repeated triggered responses, although reentry or abnormal automaticity could also be responsible. In an animal model using a voltage sensitive dye and high resolution video imaging of electrical waves, drug-induced polymorphic VT resulted from beat to beat changes in wave propagation patterns initiated by EADs or EAD-induced nonstationary vortex-like reentrant activity (",
"    <a class=\"graphic graphic_waveform graphicRef56857 \" href=\"UTD.htm?35/32/36356\">",
"     waveform 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another animal study, TdP consistently arose as a focal activity within the subendocardium, while subsequent beats were due to reentrant excitation in the form of rotating vortices [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9591/abstract/27\">",
"     27",
"    </a>",
"    ]. The VT ended when reentry terminated. The changing QRS axis usually coincided with the transient bifurcation of a predominantly single rotating vortex into two simultaneous vortices, involving the right and left ventricles separately. The bifurcation resulted from the development of functional conduction block within the right ventricle. In other cases, the axis shift was due to a single localized circuit which varied in location and orientation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that the prolonged QT interval seen in the congenital LQTS is the result of an abnormality in an ion channel and therefore in ion conductance. Observations in the genetic forms of the LQTS are consistent with this hypothesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ensuing delay in repolarization and an associated dispersion of heterogeneity may serve as the substrate upon which the following may occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heightened sympathetic tone can initiate the development of EADs and triggered activity.",
"     </li>",
"     <li>",
"      Reentry may result with the initiation and, in some instances, maintenance of an arrhythmia.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/1\">",
"      Wehrens XH, Vos MA, Doevendans PA, Wellens HJ. Novel insights in the congenital long QT syndrome. Ann Intern Med 2002; 137:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/2\">",
"      Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/3\">",
"      Jackman WM, Friday KJ, Anderson JL, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/4\">",
"      Viskin S, Alla SR, Barron HV, et al. Mode of onset of torsade de pointes in congenital long QT syndrome. J Am Coll Cardiol 1996; 28:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/5\">",
"      Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992; 262:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/6\">",
"      January CT, Riddle JM. Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res 1989; 64:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/7\">",
"      Szabo B, Sweidan R, Rajagopalan CV, Lazzara R. Role of Na+:Ca2+ exchange current in Cs(+)-induced early afterdepolarizations in Purkinje fibers. J Cardiovasc Electrophysiol 1994; 5:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/8\">",
"      Roden DM, Lazzara R, Rosen M, et al. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996; 94:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/9\">",
"      Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 1994; 23:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/10\">",
"      Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996; 28:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/11\">",
"      Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995; 6:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/12\">",
"      Ben-David J, Zipes DP. Torsades de pointes and proarrhythmia. Lancet 1993; 341:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/13\">",
"      Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/14\">",
"      Cimini MG, Brunden MN, Gibson JK. Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. Eur J Pharmacol 1992; 222:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/15\">",
"      Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996; 94:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/16\">",
"      Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996; 93:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/17\">",
"      Tan HL, Hou CJ, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995; 122:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/18\">",
"      Nattel S, Ranger S, Talajic M, et al. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 1990; 89:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/19\">",
"      Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 1997; 20:2810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/20\">",
"      Villa A, Foresti V, Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin Auton Res 1995; 5:48.",
"     </a>",
"    </li>",
"    <li>",
"     Schwartz P, Locati E, Priori E, Zaza A. Cardiac Electrophysiology: From Cell to Bedside. In: Cardiac Electrophysiology: From Cell to Bedside, Zipes D, Jalife J (Eds), WB Saunders, Philadelphia 1990. p.589.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/22\">",
"      Abildskov JA, Lux RL. Mechanisms in adrenergic dependent onset of torsades de pointes. Pacing Clin Electrophysiol 1997; 20:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/23\">",
"      Tanabe Y, Inagaki M, Kurita T, et al. Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 2001; 37:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/24\">",
"      Hirao H, Shimizu W, Kurita T, et al. Frequency-dependent electrophysiologic properties of ventricular repolarization in patients with congenital long QT syndrome. J Am Coll Cardiol 1996; 28:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/25\">",
"      Yan GX, Wu Y, Liu T, et al. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 2001; 103:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/26\">",
"      Asano Y, Davidenko JM, Baxter WT, et al. Optical mapping of drug-induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart. J Am Coll Cardiol 1997; 29:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9591/abstract/27\">",
"      El-Sherif N, Chinushi M, Caref EB, Restivo M. Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long-QT syndrome: detailed analysis of ventricular tridimensional activation patterns. Circulation 1997; 96:4392.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 955 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-D91D1357DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9591=[""].join("\n");
var outline_f9_23_9591=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Derangements in ion flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - The normal action potential",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Prolonged repolarization and EADs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Triggered activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Common precipitants of EADs and triggered activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Increased sympathetic activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dispersion of repolarization and reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initiation and maintenanance of VT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/955\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/955|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/57/927\" title=\"figure 1\">",
"      Molecular basis of LQTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/55/16253\" title=\"figure 2\">",
"      Myocardial action potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/955|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?31/46/32481\" title=\"movie 1\">",
"      Generation of the myocardial action potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/955|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 1\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/955|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/7/43134\" title=\"waveform 1\">",
"      ECG torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?35/32/36356\" title=\"waveform 2\">",
"      Mechanism of torsades de pointes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=related_link\">",
"      QT dispersion: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=related_link\">",
"      QT dispersion: Measurement and interpretation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_23_9592="Lapatinib: Drug information";
var content_f9_23_9592=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lapatinib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/31/29173?source=see_link\">",
"    see \"Lapatinib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16406986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Lapatinib-Based Regimens Less Effective Than Trastuzumab-Based Regimens in Certain Settings",
"     </span>",
"     <span class=\"collapsible-date\">",
"      March 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada, in conjunction with GlaxoSmithKline, Inc, has informed clinicians of an update to the product monograph for lapatinib (Tykerb&reg;) regarding its comparative efficacy versus trastuzumab (Herceptin&reg;) in combination with chemotherapy in HER2+ metastatic breast cancer patients; the update is based on the preplanned interim analysis of two recent trials (CEREBEL and COMPLETE).",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The COMPLETE trial (Gelmon, 2012) compared lapatinib versus trastuzumab when combined with taxane-based chemotherapy (eg, paclitaxel or docetaxel) as first-line therapy in patients with HER2+ metastatic breast cancer (n=636).  At interim analysis, progression-free survival (PFS) was found to be inferior for the lapatinib-based regimens (PFS 8.8 months; 95% CI 8.3-10.6) as compared to the trastuzumab-based regimens (PFS 11.4 months; 95% CI 10.8-13.7); with a hazard ratio of 1.48 (95%CI 1.15-1.92; p=0.003). No difference in overall survival was detected.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The CEREBEL trial (Pivot, 2012) compared the impact of lapatinib plus capecitabine and trastuzumab plus capecitabine on central nervous system metastases in patients with HER2+ metastatic breast cancer (n=475); prior therapy must have included anthracyclines or taxanes in the neoadjuvant, adjuvant, or metastatic setting. At interim analysis, progression-free survival (PFS) was found to be inferior for the lapatinib-based regimen (PFS 6.6 months) as compared to the trastuzumab-based regimen (PFS 8 months) (HR: 1.3; 95% CI: 1-1.7). Median overall survival was also inferior in the lapatinib arm (22.4 months) versus the trastuzumab arm (27.3 months) (HR: 1.58; 95% CI: 1.07-2.32).",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Based on the above interim analyses, lapatinib-based regimens are inferior to trastuzumab-based regimens in patients with HER2+ metastatic breast cancer who have not received prior trastuzumab. Lapatinib should not be used in combination with capecitabine unless patients have progressed on prior trastuzumab therapy in the metastatic setting.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26285a-eng.php",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:2em;margin-top:4em;\">",
"       Gelmon KA, Boyle F, Kaufman B, et al, \"Open-label Phase III Randomized Controlled Trial Comparing Taxane-Based Chemotherapy (Tax) With Lapatinib (L) or Trastuzumab (T) as First-Line Therapy for Women With HER2+ Metastatic Breast Cancer: Interim Analysis (IA) of NCIC CTG MA.31/GSK EGF 108919,\"",
"       <i>",
"        J Clin Oncol",
"       </i>",
"       , 2012 30(18 Suppl): LBA671 [abstract LBA671 from 2012 ASCO Annual Meeting].",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:2em;\">",
"       Pivot X, Semiglazov V, Zurawsky B, et al, \"CEREBEL (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients(Pts) With HER2+ Metastatic Breast Cancer (MBC), Treated With Lapatinib Plus Capecitabine (LC) versus Trastuzumab Plus Capecitabine (TC),\"",
"       <i>",
"        Ann Oncol",
"       </i>",
"       , 2012, 23(9 Suppl): LBA11 [abstract LBA11 from 2012 ESMO meeting].",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6190605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4424626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tykerb&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8103386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tykerb&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4424630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Anti-HER2;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor;",
"     </li>",
"     <li>",
"      Epidermal Growth Factor Receptor (EGFR) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4424668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Breast cancer, metastatic, HER2+ (with prior anthracycline, taxane and trastuzumab therapy):",
"     </b>",
"     Oral: 1250 mg once daily (in combination with capecitabine) until disease progression or unacceptable toxicity (Geyer, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Breast cancer, metastatic, HER2+, hormonal therapy indicated:",
"     </b>",
"     Oral: 1500 mg once daily (in combination with letrozole) until disease progression (Johnston, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Breast cancer, metastatic, HER2+ with brain metastases, first-line therapy (unlabeled use):",
"     </b>",
"     Oral: 1250 mg once daily (in combination with capecitabine) until disease progression or unacceptable toxicity (Bachelot, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Breast cancer, metastatic, HER2+, with progression on prior trastuzumab therapy (unlabeled use):",
"     </b>",
"     Oral: 1000 mg once daily (in combination with trastuzumab) (Blackwell, 2010; Blackwell, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Missed doses:",
"     </i>",
"     If a  dose is missed, resume with the next scheduled daily dose; do not double the dose the next day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      <i>",
"       Dosage adjustment for concomitant CYP3A4 inhibitors/inducers:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CYP3A4 inhibitors:",
"     </i>",
"     Avoid the use of concomitant strong CYP3A4 inhibitors. If concomitant use cannot be avoided, consider reducing lapatinib to 500 mg once daily with careful monitoring. When a strong CYP3A4 inhibitor is discontinued, allow ~1 week to elapse prior to adjusting the lapatinib dose upward.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CYP3A4 inducers:",
"     </i>",
"     Avoid the use of concomitant strong CYP3A4 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     If concomitant use cannot be avoided, consider gradually titrating lapatinib from 1250 mg once daily up to 4500 mg daily (in combination with capecitabine)",
"     <b>",
"      or",
"     </b>",
"     from 1500 mg once daily up to 5500 mg daily (in combination with letrozole), based on tolerability and with careful monitoring. If the strong CYP3A4 enzyme inducer is discontinued, reduce the lapatinib dose to the indicated dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     If concomitant use cannot be avoided, titrate lapatinib dose gradually upward based on tolerability. If the strong CYP3A4 enzyme inducer is discontinued, reduce the lapatinib dose over 2 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F4424669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4424670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied); however, due to the minimal renal elimination (&lt;2%), dosage adjustments may not be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4424671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe preexisting impairment (Child-Pugh class C):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     In combination with capecitabine: Reduce dose from 1250 mg once daily to 750 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     In combination with letrozole: Reduce dose from 1500 mg once daily to 1000 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatotoxicity during treatment: Discontinue permanently (do not rechallenge).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F4424672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Cardiac toxicity:",
"     </i>",
"     Discontinue treatment for at least 2 weeks for LVEF &lt; LLN  or decreased LVEF &ge; grade 2 (U.S. labeling) or decreased LVEF &ge; grade 3 (Canadian labeling); may be restarted at 1000 mg once daily (in combination with capecitabine)",
"     <b>",
"      or",
"     </b>",
"     1250 mg once daily (in combination with letrozole) if LVEF recovers to normal and patient is asymptomatic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Diarrhea:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 3 diarrhea or grade 1 or 2 diarrhea with complicating features (moderate-to-severe abdominal cramping, grade 2 or higher nausea/vomiting, decreased performance status, fever, sepsis, neutropenia, frank bleeding, or dehydration):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     U.S. labeling: Interrupt treatment; may restart at a reduced dose (from 1500 mg once daily to 1250 mg once daily or from 1250 mg once daily to 1000 mg once daily) when diarrhea resolves to &le; grade 1.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Canadian labeling: Interrupt treatment; may restart at a reduced dose (from 1500 mg once daily to 1250 mg once daily or from 1250 mg once daily to 1000 mg once daily or from 1000 mg once daily to 750 mg once daily) when diarrhea resolves to &le; grade 1.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 4 diarrhea: Permanently discontinue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Pulmonary toxicity:",
"     </i>",
"     Discontinue treatment with pulmonary symptoms indicative of interstitial lung disease or pneumonitis which are &ge; grade 3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Other toxicities:",
"     </i>",
"     Withhold for any toxicity (other than cardiac) &ge; grade 2 until toxicity resolves to &le; grade 1 and reinitiate at 1250 mg once daily; for persistent toxicity, reduce dosage to 1000 mg once daily (in combination with capecitabine)",
"     <b>",
"      or",
"     </b>",
"     1250 mg once daily (in combination with letrozole)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4424679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tykerb&reg;: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4424628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lapatinib is available",
"     <b>",
"      only",
"     </b>",
"     at specialty pharmacies through a restricted-access program, Tykerb&reg; CARES. Information is available at www.tykerbcares.com or 1-866-489-5372.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4424674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer once daily, on an empty stomach, 1 hour before or 1 hour after a meal. Take full dose at the same time each day; dividing doses throughout the day is not recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:0em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4424632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HER2 overexpressing advanced or metastatic breast cancer (in combination with capecitabine) in patients who have received prior therapy (with an anthracycline, a taxane, and trastuzumab) and HER2 overexpressing hormone receptor positive metastatic breast cancer in postmenopausal women where hormone therapy is indicated (in combination with letrozole)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9891734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment (in combination with trastuzumab) of HER2 overexpressing metastatic breast cancer which had progressed on prior trastuzumab containing therapy; treatment of HER2 overexpressing metastatic breast cancer with brain metastases",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4424622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lapatinib may be confused with dasatinib, erlotinib, imatinib, regorafenib, SUNItinib, vandetanib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4424644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported for combination therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (10% to 20%), headache (&le;14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Palmar-plantar erythrodysesthesia (hand-and-foot syndrome) (with capecitabine: 53%; grade 3: 12%), rash (28% to 44%), dry skin (10% to 13%), alopecia (&le;13%), pruritus (&le;12%), nail disorder (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (64% to 65%; grade 3: 9% to 13%; grade 4: &le;1%), nausea (31% to 44%), vomiting (17% to 26%), abdominal pain (&le;15%), mucosal inflammation (&le;15%), stomatitis (&le;14%), anorexia (&le;11%), dyspepsia (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (with capecitabine: 56%; grade 3: &lt;1%), neutropenia (with capecitabine: 22%; grade 3: 3%; grade 4: &lt;1%), thrombocytopenia (with capecitabine: 18%; grade 3: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (49% to 53%; grade 3: 2% to 6%; grade 4: &lt;1%), ALT increased (37% to 46%; grade 3: 2% to 5%; grade 4&lt;1%) total bilirubin increased (22% to 45%; grade 3: &le;4%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Limb pain (&le;12%), weakness (&le;12%), back pain (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory:Dyspnea (&le;12%), epistaxis (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: LVEF decreased (grades 1/2: 2% to 4%; grades 3/4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (&le;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, hepatotoxicity, hypersensitivity, interstitial lung disease, paronychia, pneumonitis, Prinzmetal&rsquo;s angina, QTc prolongation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4424639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lapatinib or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4424640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiotoxicity: Decreases in left ventricular ejection fraction (LVEF) have been reported (usually within the first 3 months of treatment); baseline and periodic LVEF evaluations are recommended. Interrupt treatment with decreased LVEF &ge;grade 2 or LVEF &lt;LLN; may reinitiate with a reduced dose. Use with caution in conditions which may impair left ventricular function and in patients with a history of or predisposed to (prior treatment with anthracyclines, chest wall irradiation) left ventricular dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diarrhea: Diarrhea is common (onset is generally within 6 days and duration is 4-5 days), may be severe. Diarrhea is best managed with early intervention; instruct patients to immediately report any bowel pattern changes. After first unformed stool, administer antidiarrheal agents; severe diarrhea may require hydration, electrolytes, antibiotics (if duration &gt;24 hours, fever, or grade 3/4 neutropenia), and/or treatment interruption, dose reduction, or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Hepatotoxicity (ALT or AST &gt;3 times ULN and total bilirubin &gt;2 times ULN) has been reported with lapatinib; may be severe and/or fatal.",
"     </b>",
"     Onset may occur within days to several months after treatment initiation. Monitor transaminases, bilirubin, and alkaline phosphatase (at baseline and every 4-6 weeks during treatment, and as clinically indicated); discontinue with severe changes in liver function during treatment; do not reinitiate. Use with caution in patients with hepatic impairment; dose reductions should be considered in patients with preexisting severe (Child-Pugh class C) hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pulmonary toxicity: Interstitial lung disease (ILD) and pneumonitis have been reported (with lapatinib monotherapy and combination chemotherapy); monitor for pulmonary symptoms which may indicate ILD or pneumonitis; discontinue treatment for grade 3 (or higher) pulmonary symptoms indicative of ILD or pneumonitis (eg, dyspnea, dry cough).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation has been observed; use caution in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation or with medications known to prolong the QT interval; baseline and periodic 12-lead ECG should be considered; correct electrolyte (potassium, calcium, and magnesium) abnormalities prior to and during treatment. Concurrent use with other drugs which may prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval may increase the risk of potentially-fatal arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F4424651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, CYP2C8 (moderate), CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4424650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Lapatinib. Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Lapatinib. Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Lapatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: Lapatinib may enhance the QTc-prolonging effect of Pazopanib. Lapatinib may increase the serum concentration of Pazopanib.  Management: Avoid this combination if possible. Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm as well as for other evidence of pazopanib toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Lapatinib. Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4424654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Systemic exposure of lapatinib is increased when administered with food (AUC three- to fourfold higher). Grapefruit juice may increase the levels/effects of lapatinib. Management: Administer once daily on an empty stomach, 1 hour before or 1 hour after a meal at the same time each day. Avoid grapefruit juice. Maintain adequate hydration, unless instructed to restrict fluid intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may increase metabolism and decrease lapatinib concentrations. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4424634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4424635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased pup deaths were demonstrated in animal reproduction studies. Lapatinib may cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised to avoid pregnancy during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4424637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4424638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if lapatinib is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue lapatinib or discontinue breastfeeding during treatment should take in account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F4424673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach, 1 hour before or 1 hour after a meal. (",
"     <b>",
"      Note:",
"     </b>",
"     For combination with capecitabine treatment, capecitabine should be taken with food, or within 30 minutes after a meal.) Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4735351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tykerb Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (150): $5632.31",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4424676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     LVEF (baseline and periodic), CBC with differential, liver function tests, including transaminases, bilirubin, and alkaline phosphatase (baseline and every 4-6 weeks during treatment); electrolytes including calcium, potassium, magnesium; monitor for fluid retention; ECG monitoring if at risk for QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation; symptoms of ILD or pneumonitis; monitor for diarrhea",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tykerb (AU, BR, CN, CO, CR, DO, HK, HN, ID, IL, IN, KP, MY, NZ, PA, PE, PH, SG, SV, TH, TW, UY);",
"     </li>",
"     <li>",
"      Tyverb (BE, CH, CZ, DE, DK, EE, FR, GB, GR, IE, IT, NL, NO, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4424657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tyrosine kinase (dual kinase) inhibitor; inhibits EGFR (ErbB1) and HER2 (ErbB2) by reversibly binding to tyrosine kinase, blocking phosphorylation and activation of downstream second messengers (Erk1/2 and Akt), regulating cellular proliferation and survival in ErbB- and ErbB2-expressing tumors. Combination therapy with lapatinib and endocrine therapy may overcome endocrine resistance occurring in HER2+ and hormone receptor positive disease.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4424659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Incomplete and variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99% to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; extensive via CYP3A4 and 3A5, and to a lesser extent via CYP2C19 and 2C8 to oxidized metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: ~4 hours (Burris, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (27% as unchanged drug; range 3% to 67%); urine (&lt;2%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bachelot T, Romieu G, Campone M, et al, &ldquo;Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases From HER2-Positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2013, 14(1):64-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/23122784/pubmed\" id=\"23122784\" target=\"_blank\">",
"        23122784",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baselga J, Bradbury I, Eidtmann H, et al, &ldquo;Lapatinib With Trastuzumab for HER2-Positive Early Breast Cancer (NeoALTTO): A Randomised, Open-Label, Multicentre, Phase 3 Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2012, 379(9816):633-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/22257673/pubmed\" id=\"22257673\" target=\"_blank\">",
"        22257673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blackwell KL, Burstein HJ, Storniolo AM, et al, &ldquo;Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(21):2585-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/22689807/pubmed\" id=\"22689807\" target=\"_blank\">",
"        22689807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blackwell KL, Burstein HJ, Storniolo AM, et al, &ldquo;Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(7):1124-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/20124187/pubmed\" id=\"20124187\" target=\"_blank\">",
"        20124187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burris HA 3rd, Hurwitz HI, Dees EC, et al, &ldquo;Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients with Metastatic Carcinomas,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(23):5305-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/15955900/pubmed\" id=\"15955900\" target=\"_blank\">",
"        15955900",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burris HA 3rd, Taylor CW, Jones SF, et al, &ldquo;A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients With Solid Malignancies,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2009, 15(21):6702-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/19825948/pubmed\" id=\"19825948\" target=\"_blank\">",
"        19825948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cameron D, Casey M, Oliva C, et al, &ldquo;Lapatinib Plus Capecitabine in Women With HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2010, 15(9):924-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/20736298/pubmed\" id=\"20736298\" target=\"_blank\">",
"        20736298",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chu QS, Cianfrocca ME, Goldstein LJ, et al, &ldquo;A Phase I and Pharmacokinetic Study of Lapatinib in Combination With Letrozole in Patients With Advanced Cancer,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2008, 14(14):4484-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/18628463/pubmed\" id=\"18628463\" target=\"_blank\">",
"        18628463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gelmon KA, Boyle F, Kaufman B, et al, \"Open-label Phase III Randomized Controlled Trial Comparing Taxane-Based Chemotherapy (Tax) With Lapatinib (L) or Trastuzumab (T) as First-Line Therapy for Women With HER2+ Metastatic Breast Cancer: Interim Analysis (IA) of NCIC CTG MA.31/GSK EGF 108919,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012 30(18 Suppl): LBA671 [abstract LBA671 from 2012 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geyer CE, Forster J, Lindquist D, et al &ldquo;Lapatinib Plus Capecitabine for HER2-Positive Advanced Breast Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(26):2733-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/17192538/pubmed\" id=\"17192538\" target=\"_blank\">",
"        17192538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnston S, Pippen J Jr, Pivot X, et al, &ldquo;Lapatinib Combined With Letrozole Versus Letrozole and Placebo as First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(33):5538-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/19786658/pubmed\" id=\"19786658\" target=\"_blank\">",
"        19786658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee HA, Kim EJ, Hyun SA, et al, &ldquo;Electrophysiologic Effects of the Anti-Cancer Drug Lapatinib on Cardiac Repolarization,&rdquo;",
"      <i>",
"       Basic Clin Pharmacol Toxicol",
"      </i>",
"      , 2010, 107(1):614-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/20406211/pubmed\" id=\"20406211\" target=\"_blank\">",
"        20406211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Metro G, Foglietta J, Russillo M, et al, &ldquo;Clinical Outcome of Patients With Brain Metastases From HER2-Positive Breast Cancer Treated With Lapatinib and Capecitabine,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2011, 22(3):625-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/20724575/pubmed\" id=\"20724575\" target=\"_blank\">",
"        20724575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson MH and Dolder CR, &ldquo;Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(2):261-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/16418322/pubmed\" id=\"16418322\" target=\"_blank\">",
"        16418322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pivot X, Semiglazov V, Zurawsky B, et al, \"CEREBEL (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients(Pts) With HER2+ Metastatic Breast Cancer (MBC), Treated With Lapatinib Plus Capecitabine (LC) versus Trastuzumab Plus Capecitabine (TC),\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(9 Suppl): LBA11 [abstract LBA11 from 2012 ESMO meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spector NL, Xia W, Burris H 3rd, et al, &ldquo;Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients with Advanced Malignancies,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(11):2502-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/15684311/pubmed\" id=\"15684311\" target=\"_blank\">",
"        15684311",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Storniolo AM, Pegram MD, Overmoyer B, et al, &ldquo;Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(20):3317-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/18490651/pubmed\" id=\"18490651\" target=\"_blank\">",
"        18490651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sutherland S, Ashley S, Miles D, et al, &ldquo;Treatment of HER2-Positive Metastatic Breast Cancer With Lapatinib and Capecitabine in the Lapatinib Expanded Access Programme, Including Efficacy in Brain Metastases -- the UK Experience,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2010, 102(6):995-1002.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/20179708/pubmed\" id=\"20179708\" target=\"_blank\">",
"        20179708",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wu Y, Amonkar MM, Sherrill BH, et al, &ldquo;Impact of Lapatinib plus Trastuzumab versus Single-Agent Lapatinib on Quality of Life of Patients With Trastuzumab-Refractory HER2+ Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2011, 22(12):2582-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/23/9592/abstract-text/21406472/pubmed\" id=\"21406472\" target=\"_blank\">",
"        21406472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10093 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9592=[""].join("\n");
var outline_f9_23_9592=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16406986\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6190605\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424626\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103386\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424630\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424668\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424669\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424670\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424671\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424672\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424679\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424628\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234032\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424674\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424632\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9891734\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424622\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424644\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424639\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424640\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424651\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424650\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424654\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424634\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424635\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424637\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424638\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424673\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4735351\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424676\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539985\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424657\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424659\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10093\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10093|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/31/29173?source=related_link\">",
"      Lapatinib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_23_9593="Small for gestational age infant";
var content_f9_23_9593=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Small for gestational age infant",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/23/9593/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/23/9593/contributors\">",
"     George T Mandy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/23/9593/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/23/9593/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/23/9593/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/23/9593/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/23/9593/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal growth restriction (FGR, also called intrauterine growth restriction [IUGR]) is the term used to designate a fetus that has not reached its growth potential because of genetic or environmental factors. FGR results in the birth of an infant who is small for gestational age (SGA). Mortality and morbidity are increased in SGA infants compared to those who are appropriate for gestational age (AGA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=see_link\">",
"     \"Overview of causes of and risk factors for fetal growth restriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common definition of small gestational age (SGA) refers to a weight below the 10th percentile for gestational age (",
"    <a class=\"graphic graphic_table graphicRef75060 \" href=\"UTD.htm?2/30/2541\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/1\">",
"     1",
"    </a>",
"    ]. However, this definition does not make a distinction among infants who are constitutionally small, growth-restricted and small, and not small but growth-restricted relative to their potential. As an example, as many as 70 percent of fetuses who weigh below the 10th percentile for gestational age are small simply because of constitutional factors such as female sex or maternal ethnicity, parity, or body mass index; they are not at high risk of perinatal mortality or morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moderate and severe fetal growth restrictions (FGR) are defined as birth weight in the 3",
"    <sup>",
"     rd",
"    </sup>",
"    to 10",
"    <sup>",
"     th",
"    </sup>",
"    percentile and less than 3",
"    <sup>",
"     rd",
"    </sup>",
"    percentile, respectively. Normal term infants typically weigh more than 2500 g by 37 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ponderal index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ponderal index (PI) is a ratio of body weight to length expressed as [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;PI = [weight (in g) x 100] &divide; [length (in cm)]",
"   </p>",
"   <p>",
"    With normal growth, the PI increases gradually from 30 to 37 weeks gestation and then remains constant. Decreased growth of adipose tissue and skeletal muscle, the major contributors to body weight, results in a reduced PI. Reductions in PI or other indices, such as the ratio of mid-arm to occipito-frontal circumference, can identify growth restriction in newborns whose weight is greater than the 10th percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/3\">",
"     3",
"    </a>",
"    ]. PI of less than 10th percentile reflects fetal malnutrition; PI of less than 3",
"    <sup>",
"     rd",
"    </sup>",
"    percentile indicates severe wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GROWTH CURVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthropometric data from infants born at different gestational ages have been used to generate cross-sectional growth curves [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/1,5-7\">",
"     1,5-7",
"    </a>",
"    ]. These curves are not uniform and may vary by 100 to 200 g at any gestational age. The following factors may contribute to these variations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differences in maternal characteristics, including age, parity, race, or ethnic background, socioeconomic status, and body habitus",
"     </li>",
"     <li>",
"      Inaccurate measurements of body size and estimation of gestational age",
"     </li>",
"     <li>",
"      Because preterm birth is not a normal outcome, pathologic factors that result in prematurity may adversely affect fetal growth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, a customized optimal growth curve developed for a specific fetus, which account for individual differences (ie, maternal age and ethnicity), improves the detection of fetal growth restriction (FGR) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In one report, the use of customized growth curves in a cohort of 13,661 singleton deliveries improved the ability to detect FGR and improved the ability to predict adverse neonatal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/8\">",
"     8",
"    </a>",
"    ]. Ideally, separate growth curves should be used for each sex because male infants weigh more than females at each gestational age (",
"    <a class=\"graphic graphic_table graphicRef75060 \" href=\"UTD.htm?2/30/2541\">",
"     table 1",
"    </a>",
"    ). In addition, standards that incorporate birth weight of the mother and older siblings may improve classification of small gestational age (SGA) infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Etiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Curves derived from ultrasound measurements of fetuses of known gestational age who were subsequently born healthy at term provide continuous normative values for fetal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In preterm births, mean estimated fetal weight is greater than the mean weight derived from live-born infants by gestational age because SGA infants are more likely to be born prematurely than AGA infants. As a result, estimated fetal weight growth curves compared to birth-weight-gestational standards will classify more infants as having experienced FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of fetal growth restriction (FGR) varies among populations and increases with decreasing gestational age. Approximately 10 percent of term infants in developed countries are SGA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/16\">",
"     16",
"    </a>",
"    ], compared to 23 percent of term infants in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/17\">",
"     17",
"    </a>",
"    ]. The values vary in very low birth weight infants (&lt;1500 g) depending upon whether data collection includes criteria for both birth weight and gestational age. In the NICHD Neonatal Research Network database, 22 percent of 4,438 infants with birth weight 500 to 1500 g were classified as SGA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/18\">",
"     18",
"    </a>",
"    ]. In a larger series of 20,000 very-low-birth-weight infants in which the gestational age was restricted to 25 to 30 weeks, the incidence of SGA was only 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=see_link\">",
"     \"Overview of causes of and risk factors for fetal growth restriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small gestational age (SGA) infants have either symmetric or asymmetric fetal growth restriction (FGR). Infants with symmetric FGR have reductions in both body and head growth. Symmetric FGR begins early in gestation and usually is caused by intrinsic factors such as congenital infections or chromosomal abnormalities. However, decreased nutrient supply early in development can restrict growth of all organs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants with asymmetric FGR have reduced body weight and relatively normal length and head growth. Abnormal growth typically begins in the late second or third trimesters and results from reductions in fetal nutrients that limit glycogen and fat storage yet allow continued brain growth [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/16\">",
"     16",
"    </a>",
"    ]. Mechanisms that spare brain growth are uncertain, but may include increased cerebral blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Body composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body composition is altered in SGA compared to AGA infants. Total body fat, lean mass, and bone mineral content are reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/20\">",
"     20",
"    </a>",
"    ]. Nitrogen and protein content are lower because of reduced muscle mass [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/16\">",
"     16",
"    </a>",
"    ]. Glycogen content is decreased in skeletal muscle and liver because of lower fetal plasma glucose and insulin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concentrations of alpha-amino nitrogen and most essential amino acids are lower in umbilical blood obtained by cordocentesis in FGR compared to normal fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/21\">",
"     21",
"    </a>",
"    ]. In human studies, the fetal-maternal concentration ratio of the essential amino acid leucine is reduced in FGR pregnancies with both normal and abnormal oxygenation and acid-base status. This effect is caused by decreased placental transfer of leucine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased protein catabolism by the fetal-placental unit [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal growth restriction (FGR) may be caused by maternal, placental, or fetal factors. Approximately one-third of FGRs are due to genetic causes, and two-thirds are related to the fetal environment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/23\">",
"     23",
"    </a>",
"    ]. However, no underlying etiology can be identified in at least 40 percent of SGA infants. This issue is discussed in detail elsewhere but a brief listing is provided here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=see_link\">",
"     \"Overview of causes of and risk factors for fetal growth restriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Maternal factors",
"    </span>",
"   </p>",
"   <p>",
"    (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of causes of and risk factors for fetal growth restriction\", section on 'Maternal factors'",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe maternal starvation during pregnancy",
"     </li>",
"     <li>",
"      Maternal hypoxemia",
"     </li>",
"     <li>",
"      Hematologic and immunologic disorders that cause thrombosis of the intervillous space and decrease uteroplacental perfusion",
"     </li>",
"     <li>",
"      Maternal medical disorders (eg, nephropathy, collagen vascular disease) and obstetrical complications (eg, preeclampsia) associated with vasculopathy",
"     </li>",
"     <li>",
"      Viruses and parasites (eg, rubella, toxoplasmosis, cytomegalovirus, varicella-zoster, malaria) that gain access to the fetus transplacentally or across the intact fetal membranes",
"     </li>",
"     <li>",
"      Maternal substance abuse, including cigarette smoking, alcohol consumption, and illicit drug use",
"     </li>",
"     <li>",
"      Toxic exposures, including various medications such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"       warfarin",
"      </a>",
"      , anticonvulsants, antineoplastic agents, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"       folic acid",
"      </a>",
"      antagonists",
"     </li>",
"     <li>",
"      High altitude",
"     </li>",
"     <li>",
"      Demographic variables including race, pregnancy at the extremes of reproductive life, maternal age at first childbirth, nulliparity or grand multiparity, and previous delivery of an SGA newborn",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Placental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any mismatch between fetal nutritional or respiratory demands and placental supply can result in impaired fetal growth. FGR results from an accumulation of placental injuries, such as abnormal uteroplacental vasculature, chronic inflammatory lesions, abruptio placenta, or thrombophilia-related uteroplacental pathology, and gross placental structural anomalies, such as single umbilical artery, velamentous umbilical cord insertion, and placental hemangioma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of causes of and risk factors for fetal growth restriction\", section on 'Placental factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neonatal factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Karyotypic abnormalities, such as trisomies, autosomal deletions, ring chromosomes, uniparental disomy, and confined placental mosaicism. The presence of a chromosomal abnormality often results in the appearance of FGR early in pregnancy, most likely of the symmetric type.",
"     </li>",
"     <li>",
"      Genetic syndromes, such as Bloom syndrome, dwarfism, and Russell-Silver syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35493?source=see_link\">",
"       \"Bloom syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Major congenital anomalies. In one study reviewing data from the National Birth Defects Prevention Study, infants with congenital heart disease, in particular conotruncal and septal defects, were twice as likely to be small for gestational age compared to those without a birth defect (15.2 versus 7.8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple gestation is related to fetal growth abnormalities in direct relationship to the number of fetuses present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27594?source=see_link&amp;anchor=H13#H13\">",
"       \"Neonatal outcome, complications, and management of multiple births\", section on 'Fetal growth'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small gestational age (SGA) infants appear thin with loose, peeling skin and decreased skeletal muscle mass and subcutaneous fat tissue. The face has a typical shrunken or \"wizened\" appearance, and the umbilical cord often is thin (",
"    <a class=\"graphic graphic_picture graphicRef53832 \" href=\"UTD.htm?21/6/21600\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/16\">",
"     16",
"    </a>",
"    ]. Meconium staining may be present (",
"    <a class=\"graphic graphic_picture graphicRef78143 \" href=\"UTD.htm?41/3/42033\">",
"     picture 2",
"    </a>",
"    ). In newborns with asymmetric fetal growth restriction (FGR), the head appears relatively large compared to the size of the trunk and extremities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Gestational age assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical criteria used to assess gestational age are altered in SGA infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22068?source=see_link\">",
"     \"Postnatal assessment of gestational age\"",
"    </a>",
"    .) As an example, decreased vernix production associated with reductions in either estriol synthesis or skin perfusion leads to increased exposure of the skin to amniotic fluid. This exposure results in increased desquamation and enhanced wrinkling (and more mature appearance) of the soles of the feet. Other findings are diminished breast bud formation, less mature appearance of the female genitalia, and reduced ear cartilage. The neurologic assessment is reliable in SGA infants without disorders affecting the nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small gestational age (SGA) infants have a variety of associated clinical problems beginning at birth. Severely affected term newborns deprived of oxygen and nutrients may have a difficult cardiopulmonary transition with perinatal asphyxia, meconium aspiration, or persistent pulmonary hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5387903\">",
"    <span class=\"h2\">",
"     Premature infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with fetal growth restriction (FGR) who are delivered before term also may have complications of prematurity. In a study of approximately 20,000 very-low-birth-weight infants (501 to 1500 g birth weight, 25 to 30 weeks gestation), 9 percent were SGA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/19\">",
"     19",
"    </a>",
"    ]. The SGA infants had significantly greater rates of neonatal death, necrotizing enterocolitis, and respiratory distress syndrome (RDS) (odds ratios 2.77, 1.27, 1.19, respectively) than did AGA infants. Administration of prenatal glucocorticoid reduced the risks of RDS, severe intraventricular hemorrhage, and death in SGA infants (odds ratios 0.51, 0.50, 0.54, respectively), as it does in AGA infants.",
"   </p>",
"   <p>",
"    In a multicenter European study of infants born between 24 and 31 weeks gestation, the rate of bronchopulmonary dysplasia increased with decreasing birth weight percentiles [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/25\">",
"     25",
"    </a>",
"    ]. However, there was no association with birth weight percentiles and the risk of cystic periventricular leukomalacia or grade III and IV intraventricular hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Impaired thermoregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;SGA infants have impaired thermoregulation because of increased heat loss and reduced heat production [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/16\">",
"     16",
"    </a>",
"    ]. The former is caused by reduced subcutaneous fat, whereas the latter results from both depletion of catecholamines (needed for thermogenesis by brown fat) by intrauterine stress and reduced availability of nutrient substrates. Affected infants should be cared for in a neutral thermal environment so that oxygen consumption is minimized. In one report, SGA infants had significantly higher rates of hypothermia than AGA controls (18 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose must be monitored in SGA infants because hypoglycemia is common [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The risk of hypoglycemia correlates with the severity of growth restriction. In a large retrospective study, hypoglycemia occurred in 2.4, 4.5, and 19.1 percent of infants with birth weight below 9.0, 4.3, and 1.7 percentiles, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/27\">",
"     27",
"    </a>",
"    ]. In another report, symptomatic hypoglycemia occurred in 5 percent of infants with birth weight below the 10",
"    <sup>",
"     th",
"    </sup>",
"    percentile, compared to 1 percent of those with birth weight 10",
"    <sup>",
"     th",
"    </sup>",
"    to 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SGA infants become predisposed to hypoglycemia in utero as low intrauterine insulin concentrations result in decreased glycogen synthesis and reduced glycogen stores. After delivery, a poorly coordinated response of counterregulatory hormones and peripheral insensitivity to these hormones may contribute to hypoglycemia in some infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/29\">",
"     29",
"    </a>",
"    ]. Hypoglycemia typically occurs within the first 10 hours after birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Polycythemia and hyperviscosity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycythemia and hyperviscosity occur more frequently in SGA infants. In one study, hyperviscosity was detected with a microviscometer in 18 percent of SGA infants; most had hematocrits greater than 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of polycythemia increases with the severity of growth restriction. In one report, polycythemia occurred in 9.5, 13.8, and 41.5 percent of infants with mild, moderate, and severe growth restriction, respectively, compared to 7.5 percent of AGA infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/27\">",
"     27",
"    </a>",
"    ]. Increased erythropoietin production resulting from fetal hypoxia is thought to be responsible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Impaired immune function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellular immunity can be impaired in FGR infants in the newborn period and through childhood. In a cross-sectional study, T and B peripheral lymphocytes were decreased at birth; T lymphocyte numbers became normal in later childhood, but their proliferative capacity was reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/32\">",
"     32",
"    </a>",
"    ]. Delayed cutaneous hypersensitivity to phytohemagglutinin was reduced in both newborns and children.",
"   </p>",
"   <p>",
"    Approximately 50 percent of infants born to mothers with severe hypertension (a common cause of FGR) have neutropenia that may increase their risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/33\">",
"     33",
"    </a>",
"    ]. In one study, nosocomial infection occurred more often in neutropenic than in nonneutropenic infants (55 versus 12 percent), although data are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal, neonatal, and perinatal mortality are increased in small gestational age (SGA) compared to AGA infants including premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/6,25,35-37\">",
"     6,25,35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study from a national database of nearly 3.3 million births in the United States in 2002 reported 1956 deaths due to sudden infant death syndrome (SIDS), 2012 sudden unexpected deaths, and 11,592 other deaths. SGA was associated with an increased risk of SIDS (OR 1.65, 95% CI 1.47-1.85), sudden unexpected death (OR 1.78, 95% CI 1.59-2), and other causes of death (OR 4.68, 95% CI 4.49-4.88) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another population study of more than two million births in California, fetal, neonatal, and perinatal mortality in term infants was 20 to 30 times higher with birth weight 1500 to 2500 g than for AGA infants (",
"      <a class=\"graphic graphic_table graphicRef65356 \" href=\"UTD.htm?13/41/13979\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef69065 \" href=\"UTD.htm?13/34/13867\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef75652 \" href=\"UTD.htm?13/39/13947\">",
"       table 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/6\">",
"       6",
"      </a>",
"      ]. When birth weight was less than 1500 g, mortality rates increased 70 to 100 times.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110678135\">",
"    <span class=\"h2\">",
"     Premature SGA infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates increase with decreasing gestational age and decreasing birth percentiles as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the previously mentioned multi-center European study of premature infants with gestational ages between 24 and 31 weeks, mortality rate increased with decreasing birth percentiles except for infants who were large for gestational age (&gt;90",
"      <sup>",
"       th",
"      </sup>",
"      percentile) as follows [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/25\">",
"       25",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      &lt;10",
"      <sup>",
"       th",
"      </sup>",
"      percentile &ndash; 26 percent",
"     </li>",
"     <li>",
"      10",
"      <sup>",
"       th",
"      </sup>",
"      to 24",
"      <sup>",
"       th",
"      </sup>",
"      percentile &ndash; 20 percent",
"     </li>",
"     <li>",
"      25",
"      <sup>",
"       th",
"      </sup>",
"      to 49",
"      <sup>",
"       th",
"      </sup>",
"      percentile &ndash; 15 percent",
"     </li>",
"     <li>",
"      50",
"      <sup>",
"       th",
"      </sup>",
"      to 74",
"      <sup>",
"       th",
"      </sup>",
"      percentile &ndash; 13 percent",
"     </li>",
"     <li>",
"      75",
"      <sup>",
"       th",
"      </sup>",
"      to 89",
"      <sup>",
"       th",
"      </sup>",
"      percentile &ndash; 12 percent",
"     </li>",
"     <li>",
"      &gt;90",
"      <sup>",
"       th",
"      </sup>",
"      percentile &ndash; 16 percent",
"      <br/>",
"      <br/>",
"      Perinatal mortality increases as growth restriction becomes more severe, rising abruptly when birth weight is below the 6",
"      <sup>",
"       th",
"      </sup>",
"      percentile (",
"      <a class=\"graphic graphic_figure graphicRef56263 \" href=\"UTD.htm?13/6/13422\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/38\">",
"       38",
"      </a>",
"      ]. Congenital malformations, perinatal asphyxia, and transitional cardiorespiratory disorders contribute to the high mortality rate in term infants. Complications of prematurity play a greater role as gestational age decreases [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the French EPIPAGE study that prospectively followed premature live births born in 1997, 536 of the 2846 infants born alive were SGA [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/39\">",
"       39",
"      </a>",
"      ]. Mortality increased with decreasing gestational age and birth percentiles as follows: &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among the infants born between 24 and 28 week gestation, the mortality was 30, 42, and 62 percent for infants born AGA (birth weight &gt;20",
"      <sup>",
"       th",
"      </sup>",
"      percentile), mild SGA (birth weight between the 10",
"      <sup>",
"       th",
"      </sup>",
"      and 19",
"      <sup>",
"       th",
"      </sup>",
"      percentile), and SGA (birth weight &lt;10",
"      <sup>",
"       th",
"      </sup>",
"      percentile), respectively.",
"     </li>",
"     <li>",
"      Among the infants born between 29 and 32 weeks gestation, the mortality was 4.8, 4.2, and 10.5 percent for infants born AGA, mild SGA, and SGA, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a fetus is known to be growth restricted, problems can be anticipated beginning at birth. Delivery of severely affected infants should be planned at a perinatal center. The etiology of fetal growth restriction (FGR) should be investigated in affected infants when it is not known prior to delivery. In approximately 40 percent of cases, no cause can be identified. Specific attention should be given to congenital malformations, chromosomal abnormalities, and congenital infection, in addition to the many other factors listed above. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because small gestational age (SGA) infants have impaired thermoregulation, heat loss should be avoided by immediate drying and placement under a radiant warmer. Prompt resuscitation, including clearing the airway of meconium if needed, should be instituted. Appropriate therapy is begun for disorders of transition, including meconium aspiration pneumonia, myocardial dysfunction, or persistent pulmonary hypertension, that develop.",
"   </p>",
"   <p>",
"    Enteral feeding should be started early infants at volumes appropriate for the infant's weight, including premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/40\">",
"     40",
"    </a>",
"    ]. In infants who have severe perinatal asphyxia, are ill, or do not tolerate enteral feeds, feedings should be withheld and intravenous nutrition provided.",
"   </p>",
"   <p>",
"    Monitoring for hypoglycemia is initiated within one to two hours after birth. Samples are obtained before feedings. Surveillance is continued in infants with low plasma glucose concentrations (less than 40",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    2.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    until feedings are well established and glucose values have normalized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SGA infants who are premature or have birth asphyxia are at risk for hypocalcemia. Ionized calcium concentrations should be monitored starting at 12 hours after birth, and adequate calcium intake should be provided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=see_link\">",
"     \"Neonatal hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small gestational age (SGA) infants are at risk for impaired growth and neurodevelopment. Subsequent disorders in adults may also result from fetal growth restriction (FGR).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Physical growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;SGA infants have different patterns of growth depending upon the etiology and the severity of growth restriction. In moderately affected infants, growth during the first 6 to 12 months after birth may be accelerated, resulting in attainment of normal size in most children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In one study, for example, 87 percent of 3,650 term infants with birth length more than two standard deviations below the mean had normal height at 1 year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/42\">",
"     42",
"    </a>",
"    ]. However, in a report of national survey data, SGA infants appeared to catch up in weight in the first six months, but maintained a deficit in height of approximately 0.75 standard deviation units through 47 months compared to AGA infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, severely affected SGA infants frequently weigh less and are shorter than AGA infants throughout childhood and adolescence. In one report, for example, body measurements at age 17 years in adolescents who had birth weight less than the 3",
"    <sup>",
"     rd",
"    </sup>",
"    percentile were compared to those who were AGA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/44\">",
"     44",
"    </a>",
"    ]. The average height was significantly less in the SGA group (169 versus 175 cm and 159 versus 163 cm, for boys and girls respectively). In addition, the adolescent height of SGA newborns was more likely to be less than the 10",
"    <sup>",
"     th",
"    </sup>",
"    percentile (odds ratio 4.13 and 3.32, for boys and girls respectively).",
"   </p>",
"   <p>",
"    The pathophysiology of growth restriction and the efficacy of growth hormone therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3672?source=see_link\">",
"     \"Growth hormone treatment for children born small for gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Neurodevelopment",
"    </span>",
"    &nbsp;&mdash;&nbsp;SGA infants appear to be at increased risk for neurodevelopmental abnormalities and decreased cognitive performance, although the data are conflicting. Most older studies of outcome are difficult to interpret because of small sample sizes and inclusion of infants with underlying conditions and neonatal complications that affect outcome. Affected children with neonatal complications had significantly lower IQ scores and poorer neurodevelopmental outcome at three years than did those with uncomplicated courses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/45\">",
"     45",
"    </a>",
"    ]. When complications such as birth asphyxia were excluded in another report, term SGA infants had a good prognosis for cognitive and neurologic development at 13 to 19 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FGR appear to effect neurodevelopment and behavior in adolescents and young adults, as demonstrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, adolescents born at term with severe FGR (&le;3",
"      <sup>",
"       rd",
"      </sup>",
"      percentile) had intelligence test scores comparable to those born AGA, but affected males were significantly more likely to have less than 12 years of schooling or attend a vocational school (odds ratio 2.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, adolescents born SGA (&le;3",
"      <sup>",
"       rd",
"      </sup>",
"      percentile) at term were more likely to have learning difficulties (32 versus 18 percent) compared to those born AGA, although cognitive ability was not affected [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/48\">",
"       48",
"      </a>",
"      ]. Learning difficulties were related to the severity of growth restriction but not symmetry. Attentional problems were more frequent in the SGA girls, but not boys.",
"     </li>",
"     <li>",
"      In a population-based cohort study of young adult Swedish males evaluated at the time of military conscription, multiple logistic regression analysis demonstrated low intellectual performance scores were associated with birth weight &lt;2 SDS below the mean (OR 1.22, 95% CI 1.13-1.33), birth length &lt;2 SDS below the mean (OR 1.33, 95% CI 1.22-1.46), and birth head circumference &lt;2 SDS below the mean (OR 1.28, 95% 1.20-1.37) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a registry-based cohort Norwegian study of 36,604 term SGA singleton births, 104 patients died in the neonatal period and 69 developed cerebral palsy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/50\">",
"       50",
"      </a>",
"      ]. Retrospective review of cases suggested that cerebral palsy was due to an antenatal cause in about 90 percent of affected SGA children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Premature infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive and neurodevelopmental abnormalities are more common in survivors who were growth restricted premature infants compared with those who were AGA and born at the same gestational age.",
"   </p>",
"   <p>",
"    In comparison to AGA controls, children who were premature and growth restricted are more likely to have:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower scores on cognitive testing [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/37,39,51\">",
"       37,39,51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      School difficulties or require special education [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/37,39\">",
"       37,39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Gross motor and minor neurologic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Behavioral problems (attention deficit hyperactivity syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perinatal factors &ndash; Other perinatal factors that may affect neurodevelopmental outcome were evaluated in a cohort of 282 SGA infants (mean gestational age and birth weight 36.5 weeks and 2095 g, respectively) born in the mid 1990s in New Zealand and examined at 18 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/52\">",
"       52",
"      </a>",
"      ]. The proportion of SGA infants with low Mental Developmental Index (MDI) scores of the Bayley Scales of Infant Development was significantly less when mothers had pregnancy-induced hypertension compared to normal blood pressure in pregnancy (23 versus 44 percent). Although hypertension may be protective, a more likely explanation is that other causes of SGA are associated with a greater risk of poor outcome. Factors associated with low Psychomotor Development Index (PDI) scores were not being breast fed at 3 months, long hospital stay, and need for mechanical ventilation. A low Behavioral Rating Scale (BRS) score was associated with small head circumference at birth and increased arterial base deficit in cord blood. No relationship was found between maternal demographic factors, including age, ethnicity, parity, smoking, education, or severe deprivation, and abnormal MDI, PDI, or BRS scores.",
"     </li>",
"     <li>",
"      Postnatal growth &ndash; Excessive or poor postnatal weight gain during the first four months of life appears to have a negative impact on neurodevelopmental outcome. This was illustrated in a study from the Collaborative Perinatal Project (CPP) that evaluated the cognitive outcome of 463 children who were SGA at birth at 7 years of age using the Wechsler Scale of Children's Intelligence (WISC) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/53\">",
"       53",
"      </a>",
"      ]. Children who gained less than 1200 g or more than 5000 g during the first four months of life had lower WISC scores than children with weight gains between these two extremes. In addition, body mass index at 7 years of age correlated with postnatal weight gain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Relationship to adult disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults who were SGA infants may be at increased risk for ischemic heart disease and related disorders. This proposed association, (Fetal origins of adult disease theory or Barker hypothesis) between FGR and adult coronary and vascular disease is based upon the assumption that fetal undernutrition results in changes in vascular development that predisposes to adult disease, such as hypertension, stroke, diabetes, and hypercholesterolemia (Barker hypothesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association with SGA and adult ischemic heart disease was best illustrated in a cohort study of 6425 subjects born SGA or preterm at four major Swedish delivery units between 1925 through 1949 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/57\">",
"     57",
"    </a>",
"    ]. At follow-up during the time period from 1987 to 2002, the risk of ischemic heart disease was greater in subjects who were born SGA compared to age- and gender-matched controls who were born AGA with gestational ages greater than 35 weeks (adjusted hazard ratio 1.64, 95% CI 1.23-2.18). The negative association between poor fetal growth and risk of ischemic heart disease was independent of gestational age.",
"   </p>",
"   <p>",
"    Other studies demonstrated an increase in aortic wall thickness (a marker of early atherosclerosis) by ultrasonography in infants with fetal growth restriction compared to infants with normal birthweight [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], and increased aortic stiffness [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, one postmortem study in children between 1 and 13 years of age demonstrated an inverse relationship between birth weight and the extent and severity of aortic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/61\">",
"     61",
"    </a>",
"    ]. Although these findings are suggestive of a fetal contribution to later cardiovascular risk, long-term longitudinal studies are needed to more fully understand the clinical significance of these changes and whether they contribute to atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=see_link\">",
"     \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, this hypothesis (fetal origins of the adult disease theory) is not universally accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. In a smaller case cohort study, no significant differences in health quality outcomes were noted between 50 year old adults who were born full term with a birth weight below the 10",
"    <sup>",
"     th",
"    </sup>",
"    percentile (defined as FGR) compared to controls with birth weights greater than the 10",
"    <sup>",
"     th",
"    </sup>",
"    percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/63\">",
"     63",
"    </a>",
"    ]. Other studies have found either no association between birthweight to adult blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/64\">",
"     64",
"    </a>",
"    ], or prematurity not FGR increased the risk of high blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/23/9593/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=see_link\">",
"     \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2522410\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small gestational age (SGA) is the result of fetal growth restriction (FGR) caused by a genetic or fetal environmental factors that result in the inability of the fetus to reach its growth potential. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=see_link\">",
"       \"Overview of causes of and risk factors for fetal growth restriction\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common definition of SGA is a birth weight that is below the 10",
"      <sup>",
"       th",
"      </sup>",
"      percentile for gestational age (",
"      <a class=\"graphic graphic_table graphicRef75060 \" href=\"UTD.htm?2/30/2541\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality and morbidity are increased in SGA infants when compared with infants who have appropriate birth weights (birth weight &ge;10",
"      <sup>",
"       th",
"      </sup>",
"      percentile) for gestational age (AGA).",
"     </li>",
"     <li>",
"      Infants who are SGA typically appear thin with loose, peeling skin, and decreased skeletal muscle mass and subcutaneous fat tissue. The face generally has a shrunken or \"wizened\" appearance, and the umbilical cord often is thin (",
"      <a class=\"graphic graphic_picture graphicRef53832 \" href=\"UTD.htm?21/6/21600\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Complications associated with SGA during the neonatal period include prematurity, poor thermoregulation, hypoglycemia, polycythemia resulting in hyperviscosity, and impaired immune function. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Population-based data demonstrate a 20- to 30-fold increase in mortality between term infants born AGA compared with those born SGA with birth weights of 1500 to 2500 g, and rises to 70- to 100-fold increase with births weights below 1500 g. The mortality rate also increases with decreasing gestation.",
"     </li>",
"     <li>",
"      Management of infants with SGA includes (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Identifying and if possible, treating the underlying cause of FGR. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive care including avoidance of heat loss, initiation of enteral feeds as early as possible, and monitoring for potential complications, such as hypoglycemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-term complications of patients who were born SGA include impaired growth and neurodevelopment. In addition, adults who were SGA infants may be predisposed to cardiovascular disease because of changes in vascular development. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/1\">",
"      Battaglia FC, Lubchenco LO. A practical classification of newborn infants by weight and gestational age. J Pediatr 1967; 71:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/2\">",
"      Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol 1996; 87:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/3\">",
"      Chard T, Costeloe K, Leaf A. Evidence of growth retardation in neonates of apparently normal weight. Eur J Obstet Gynecol Reprod Biol 1992; 45:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/4\">",
"      Miller HC, Hassanein K. Diagnosis of impaired fetal growth in newborn infants. Pediatrics 1971; 48:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/5\">",
"      Arbuckle TE, Wilkins R, Sherman GJ. Birth weight percentiles by gestational age in Canada. Obstet Gynecol 1993; 81:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/6\">",
"      Williams RL, Creasy RK, Cunningham GC, et al. Fetal growth and perinatal viability in California. Obstet Gynecol 1982; 59:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/7\">",
"      Brenner WE, Edelman DA, Hendricks CH. A standard of fetal growth for the United States of America. Am J Obstet Gynecol 1976; 126:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/8\">",
"      Figueras F, Figueras J, Meler E, et al. Customised birthweight standards accurately predict perinatal morbidity. Arch Dis Child Fetal Neonatal Ed 2007; 92:F277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/9\">",
"      Gardosi J. Customized growth curves. Clin Obstet Gynecol 1997; 40:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/10\">",
"      Gardosi J, Chang A, Kalyan B, et al. Customised antenatal growth charts. Lancet 1992; 339:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/11\">",
"      Skjaerven R, Gjessing HK, Bakketeig LS. New standards for birth weight by gestational age using family data. Am J Obstet Gynecol 2000; 183:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/12\">",
"      Di Battista E, Bertino E, Benso L, et al. Longitudinal distance standards of fetal growth. Intrauterine and Infant Longitudinal Growth Study: IILGS. Acta Obstet Gynecol Scand 2000; 79:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/13\">",
"      Gardosi J. The application of individualised fetal growth curves. J Perinat Med 1998; 26:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/14\">",
"      Vik T, Vatten L, Jacobsen G, Bakketeig LS. Prenatal growth in symmetric and asymmetric small-for-gestational-age infants. Early Hum Dev 1997; 48:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/15\">",
"      Cooke RW. Conventional birth weight standards obscure fetal growth restriction in preterm infants. Arch Dis Child Fetal Neonatal Ed 2007; 92:F189.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson MS, Hay WW. Intrauterine growth restriction and the small-for-gestational-age infant. In: Neonatology Pathophysiology and Management of the Newborn, 5th ed, Avery GB, Fletcher MA, MacDonald MG (Eds), Lippincott Williams and Wilkins, Philadelphia 1999. p.411.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/17\">",
"      de Onis M, Bl&ouml;ssner M, Villar J. Levels and patterns of intrauterine growth retardation in developing countries. Eur J Clin Nutr 1998; 52 Suppl 1:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/18\">",
"      Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001; 107:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/19\">",
"      Bernstein IM, Horbar JD, Badger GJ, et al. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford Network. Am J Obstet Gynecol 2000; 182:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/20\">",
"      Lapillonne A, Braillon P, Claris O, et al. Body composition in appropriate and in small for gestational age infants. Acta Paediatr 1997; 86:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/21\">",
"      Cetin I, Corbetta C, Sereni LP, et al. Umbilical amino acid concentrations in normal and growth-retarded fetuses sampled in utero by cordocentesis. Am J Obstet Gynecol 1990; 162:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/22\">",
"      Cetin I. Amino acid interconversions in the fetal-placental unit: the animal model and human studies in vivo. Pediatr Res 2001; 49:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/23\">",
"      Wollmann HA. Intrauterine growth restriction: definition and etiology. Horm Res 1998; 49 Suppl 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/24\">",
"      Malik S, Cleves MA, Zhao W, et al. Association between congenital heart defects and small for gestational age. Pediatrics 2007; 119:e976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/25\">",
"      Zeitlin J, El Ayoubi M, Jarreau PH, et al. Impact of fetal growth restriction on mortality and morbidity in a very preterm birth cohort. J Pediatr 2010; 157:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/26\">",
"      Doctor BA, O'Riordan MA, Kirchner HL, et al. Perinatal correlates and neonatal outcomes of small for gestational age infants born at term gestation. Am J Obstet Gynecol 2001; 185:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/27\">",
"      Kramer MS, Olivier M, McLean FH, et al. Impact of intrauterine growth retardation and body proportionality on fetal and neonatal outcome. Pediatrics 1990; 86:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/28\">",
"      Holtrop PC. The frequency of hypoglycemia in full-term large and small for gestational age newborns. Am J Perinatol 1993; 10:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/29\">",
"      Hawdon JM, Weddell A, Aynsley-Green A, Ward Platt MP. Hormonal and metabolic response to hypoglycaemia in small for gestational age infants. Arch Dis Child 1993; 68:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/30\">",
"      Hakanson DO, Oh W. Hyperviscosity in the small-for-gestational age infant. Biol Neonate 1980; 37:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/31\">",
"      Snijders RJ, Abbas A, Melby O, et al. Fetal plasma erythropoietin concentration in severe growth retardation. Am J Obstet Gynecol 1993; 168:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/32\">",
"      Ferguson AC. Prolonged impairment of cellular immunity in children with intrauterine growth retardation. J Pediatr 1978; 93:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/33\">",
"      Mouzinho A, Rosenfeld CR, Sanchez PJ, Risser R. Effect of maternal hypertension on neonatal neutropenia and risk of nosocomial infection. Pediatrics 1992; 90:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/34\">",
"      Gray PH, Rodwell RL. Neonatal neutropenia associated with maternal hypertension poses a risk for nosocomial infection. Eur J Pediatr 1999; 158:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/35\">",
"      Wennergren M, Wennergren G, Vilbergsson G. Obstetric characteristics and neonatal performance in a four-year small for gestational age population. Obstet Gynecol 1988; 72:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/36\">",
"      Malloy MH. Size for gestational age at birth: impact on risk for sudden infant death and other causes of death, USA 2002. Arch Dis Child Fetal Neonatal Ed 2007; 92:F473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/37\">",
"      Kok JH, den Ouden AL, Verloove-Vanhorick SP, Brand R. Outcome of very preterm small for gestational age infants: the first nine years of life. Br J Obstet Gynaecol 1998; 105:162.",
"     </a>",
"    </li>",
"    <li>",
"     Manning FA. Intrauterine growth retardation. In: Fetal Medicine: Principles and Practice, Appleton and Lange, Norwalk, CT 1995. p.307.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/39\">",
"      Guellec I, Lapillonne A, Renolleau S, et al. Neurologic outcomes at school age in very preterm infants born with severe or mild growth restriction. Pediatrics 2011; 127:e883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/40\">",
"      Leaf A, Dorling J, Kempley S, et al. Early or delayed enteral feeding for preterm growth-restricted infants: a randomized trial. Pediatrics 2012; 129:e1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/41\">",
"      Fitzhardinge PM, Steven EM. The small-for-date infant. II. Neurological and intellectual sequelae. Pediatrics 1972; 50:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/42\">",
"      Karlberg J, Albertsson-Wikland K. Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res 1995; 38:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/43\">",
"      Hediger ML, Overpeck MD, Maurer KR, et al. Growth of infants and young children born small or large for gestational age: findings from the Third National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med 1998; 152:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/44\">",
"      Paz I, Seidman DS, Danon YL, et al. Are children born small for gestational age at increased risk of short stature? Am J Dis Child 1993; 147:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/45\">",
"      Fattal-Valevski A, Leitner Y, Kutai M, et al. Neurodevelopmental outcome in children with intrauterine growth retardation: a 3-year follow-up. J Child Neurol 1999; 14:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/46\">",
"      Westwood M, Kramer MS, Munz D, et al. Growth and development of full-term nonasphyxiated small-for-gestational-age newborns: follow-up through adolescence. Pediatrics 1983; 71:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/47\">",
"      Paz I, Gale R, Laor A, et al. The cognitive outcome of full-term small for gestational age infants at late adolescence. Obstet Gynecol 1995; 85:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/48\">",
"      O'Keeffe MJ, O'Callaghan M, Williams GM, et al. Learning, cognitive, and attentional problems in adolescents born small for gestational age. Pediatrics 2003; 112:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/49\">",
"      Bergvall N, Iliadou A, Tuvemo T, Cnattingius S. Birth characteristics and risk of low intellectual performance in early adulthood: are the associations confounded by socioeconomic factors in adolescence or familial effects? Pediatrics 2006; 117:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/50\">",
"      Stoknes M, Andersen GL, Dahlseng MO, et al. Cerebral palsy and neonatal death in term singletons born small for gestational age. Pediatrics 2012; 130:e1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/51\">",
"      McCarton CM, Wallace IF, Divon M, Vaughan HG Jr. Cognitive and neurologic development of the premature, small for gestational age infant through age 6: comparison by birth weight and gestational age. Pediatrics 1996; 98:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/52\">",
"      McCowan LM, Pryor J, Harding JE. Perinatal predictors of neurodevelopmental outcome in small-for-gestational-age children at 18 months of age. Am J Obstet Gynecol 2002; 186:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/53\">",
"      Pylipow M, Spector LG, Puumala SE, et al. Early postnatal weight gain, intellectual performance, and body mass index at 7 years of age in term infants with intrauterine growth restriction. J Pediatr 2009; 154:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/54\">",
"      Barker DJ. Early growth and cardiovascular disease. Arch Dis Child 1999; 80:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/55\">",
"      Barker DJ. Fetal origins of coronary heart disease. BMJ 1995; 311:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/56\">",
"      Barker DJ, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. BMJ 1993; 306:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/57\">",
"      Kaijser M, Bonamy AK, Akre O, et al. Perinatal risk factors for ischemic heart disease: disentangling the roles of birth weight and preterm birth. Circulation 2008; 117:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/58\">",
"      Skilton MR, Evans N, Griffiths KA, et al. Aortic wall thickness in newborns with intrauterine growth restriction. Lancet 2005; 365:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/59\">",
"      Skilton MR. Intrauterine risk factors for precocious atherosclerosis. Pediatrics 2008; 121:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/60\">",
"      Bradley TJ, Potts JE, Lee SK, et al. Early changes in the biophysical properties of the aorta in pre-adolescent children born small for gestational age. J Pediatr 2010; 156:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/61\">",
"      Napoli C, Glass CK, Witztum JL, et al. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 1999; 354:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/62\">",
"      Norman M, Bonamy AK. Aortic wall thickening in utero. Lancet 2005; 365:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/63\">",
"      Spence D, Alderdice FA, Stewart MC, et al. Does intrauterine growth restriction affect quality of life in adulthood? Arch Dis Child 2007; 92:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/64\">",
"      Huxley R, Neil A, Collins R. Unravelling the fetal origins hypothesis: is there really an inverse association between birthweight and subsequent blood pressure? Lancet 2002; 360:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/65\">",
"      Siewert-Delle A, Ljungman S. The impact of birth weight and gestational age on blood pressure in adult life: a population-based study of 49-year-old men. Am J Hypertens 1998; 11:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/23/9593/abstract/66\">",
"      Keijzer-Veen MG, Finken MJ, Nauta J, et al. Is blood pressure increased 19 years after intrauterine growth restriction and preterm birth? A prospective follow-up study in The Netherlands. Pediatrics 2005; 116:725.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5062 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9593=[""].join("\n");
var outline_f9_23_9593=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2522410\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ponderal index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GROWTH CURVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Body composition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Maternal factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Placental factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neonatal factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Gestational age assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5387903\">",
"      Premature infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Impaired thermoregulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Polycythemia and hyperviscosity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Impaired immune function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110678135\">",
"      Premature SGA infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Physical growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Neurodevelopment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Premature infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Relationship to adult disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2522410\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5062\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5062|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/6/13422\" title=\"figure 1\">",
"      SGA morbidity mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5062|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/6/21600\" title=\"picture 1\">",
"      Severe SGA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/3/42033\" title=\"picture 2\">",
"      SGA meconium stained",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5062|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/30/2541\" title=\"table 1\">",
"      10th percentile by gestational age and sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/41/13979\" title=\"table 2\">",
"      SGA fetal mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/34/13867\" title=\"table 3\">",
"      SGA neonatal mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/39/13947\" title=\"table 4\">",
"      SGA perinatal mortality",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35493?source=related_link\">",
"      Bloom syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3672?source=related_link\">",
"      Growth hormone treatment for children born small for gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=related_link\">",
"      Neonatal hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27594?source=related_link\">",
"      Neonatal outcome, complications, and management of multiple births",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=related_link\">",
"      Overview of causes of and risk factors for fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22068?source=related_link\">",
"      Postnatal assessment of gestational age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_23_9594="EM hydroxychloroquine cardiomyopathy";
var content_f9_23_9594=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Electron microscopy of cardiomyocytes in hydroxychloroquine cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The EM at 17600x magnification shows sarcomere drop out (between thick arrows) caused by proliferation of lysosomes&nbsp;that are at various stages of condensation. The arrowhead points to a lysosome with a single membrane prior to condensation. The thin yellow arrow points to a lysosome with lamellated membrane structures that has undergone condensation.",
"    <div class=\"footnotes\">",
"     EM: electron microscopy.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of J Alroy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9594=[""].join("\n");
var outline_f9_23_9594=null;
var title_f9_23_9595="Questions used to assess possibility of pregnancy";
var content_f9_23_9595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Excluding pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Pregnancy can be reasonably excluded if a client answers YES to any of the following questions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          Have you abstained from sexual intercourse since your last menstrual period?",
"         </li>",
"         <li>",
"          Have you had a normal menstrual period within the past 7 days?",
"         </li>",
"         <li>",
"          Have you been using a reliable form of contraception consistently and correctly?",
"         </li>",
"         <li>",
"          Have you had a miscarriage or abortion within the past 7 days?",
"         </li>",
"         <li>",
"          Have you had a baby within the past 4 weeks?",
"         </li>",
"         <li>",
"          Have you had a baby within the past 6 months AND are you fully or nearly-fully breastfeeding AND have you not had a menstrual period since the delivery?",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: a checklist developed by Family Health International in 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9595=[""].join("\n");
var outline_f9_23_9595=null;
var title_f9_23_9596="Healthy weight nutrition tips A";
var content_f9_23_9596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for maintaining a healthy weight: Nutrition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Phase I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Choose sugar-free beverages or low-fat milk only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Choose sugar-free beverages, water or low-fat (skim, one-half percent, and 1 percent) milk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limit milk to 16 to 24 ounces per day. Avoid flavored milks, including fat-free versions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Have fast food no more than once a week, and try the following healthier options:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Choose plain hamburger kid's meal with water, diet soda, or skim milk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Try a grilled chicken sandwich ordered without mayonnaise with a piece of fruit from home.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Try a 6-inch, low-fat Subway sandwich (ordered without mayonnaise, cheese, or oils), with baked chips or pretzels.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid burgers with double meat, cheese, bacon, mayonnaise, and super-sized french fries.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Choose three meals with one snack per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healthy breakfast ideas: two pieces whole wheat toast with a glass of skim milk; small bowl of cereal such as bran flakes, Cheerios or old-fashioned oat meal with skim milk; or a fat-free yogurt and a piece of fresh fruit.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healthy snacks include fresh fruit, fat-free yogurt, or low-fat popcorn.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limit snacks to one serving size.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Try the Plate Method at dinner. Design a dinner plate with one-half a plate of vegetables, one-quarter plate of lean meat, and one-quarter plate of starch or starchy vegetables (potatoes, corn, or peas) (see",
"        <a href=\"file://www.choosemyplate.gov\" target=\"_blank\">",
"         www.choosemyplate.gov",
"        </a>",
"        ). Avoid second helpings.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9596=[""].join("\n");
var outline_f9_23_9596=null;
var title_f9_23_9597="Comparison of the actions of ACE inhibitors and ARBs";
var content_f9_23_9597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Comparison of the actions of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 227px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACE: angiotensin converting enzyme; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9597=[""].join("\n");
var outline_f9_23_9597=null;
var title_f9_23_9598="Patient satisfaction post LVRS";
var content_f9_23_9598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postoperative patient overall satisfaction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 294px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ciccone, AM, Meyers, BF, Guthrie, TJ, et al. Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thor Card Surg 2003; 125:513.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9598=[""].join("\n");
var outline_f9_23_9598=null;
var title_f9_23_9599="Neuropathic disease of foot";
var content_f9_23_9599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neuropathic disease of foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 237px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain radiograph of the foot demonstrating features typical of neuropathic joint disease involving the tarsometatarsal joint spaces (arrows); there is destruction of the joints and adjacent bones, infralateral subluxation of the metatarsal bones with respect to the tarsal bones, and proliferative new bone formation, including extensive intertarsal degenerative change.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_23_9599=[""].join("\n");
var outline_f9_23_9599=null;
